Mechanisms of Epigenetic Plasticity in PDAC
PDAC表观遗传可塑性机制
基本信息
- 批准号:10211135
- 负责人:
- 金额:$ 50.69万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-04-01 至 2026-03-31
- 项目状态:未结题
- 来源:
- 关键词:ATAC-seqAblationBiological ModelsBypassCharacteristicsChromatin Conformation Capture and SequencingClinicalComplexDevelopmentDisease OutcomeEpigenetic ProcessEquilibriumExtinction (Psychology)GatekeepingGenesGeneticGenetic EngineeringGenetic ScreeningGenetic TranscriptionGenomicsGrantHomeostasisHumanKRAS oncogenesisLabelLesionMaintenanceMalignant - descriptorMalignant NeoplasmsMetabolicModelingMolecularMolecular TargetMusMutationNecrosisNeoplasm MetastasisNoduleOncogenicOncoproteinsOralOutputPancreasPancreatic Ductal AdenocarcinomaPathway interactionsPharmaceutical PreparationsPopulationProteinsRefractoryRelapseReporterResearchResistanceResistance developmentRoleRouteSignal TransductionStressSystemTechniquesTherapeuticTherapeutic AgentsTimeTumor Cell Invasionaddictioncancer therapychemical geneticschromatin remodelingdriving forceeffective therapyexperimental studyflexibilityfollow-upimprovedin vivoin vivo evaluationinhibitor/antagonistinsightinterestloss of functionmouse modelneoplastic cellnext generationnovel therapeutic interventiononcogene addictionpancreatic ductal adenocarcinoma cellpancreatic ductal adenocarcinoma modelpredictive modelingpreventprogenitorresponsesmall moleculestemstem cellsstem-like cellsynergismtheoriestherapy resistanttranscription factortreatment strategytumortumor growthtumor microenvironmenttumor progressionvirtual
项目摘要
Pancreatic ductal adenocarcinoma (PDAC) is one of the most deadly human cancers and in ~95%
of cases driven by oncogenic mutations of Kras. Unfortunately, attempts to directly inhibit
oncogenic Kras or Ras effector pathways have been largely ineffective in treating PDAC due to
the development of resistance. Yap (Yes-associated-protein), an oncogenic transcription
regulator, not only is required for PDAC progression but also confers resistance to extinction of
oncogenic Kras signaling and other therapeutic agents in advanced PDAC tumors. Using a next-
generation inducible genetic engineered mouse model, we discovered that even though PDAC
tumors rely on Yap to maintain the transcriptional output necessary for tumor growth and survival,
a subpopulation of tumor cells with stem/progenitor-like characteristics undergo epigenetic
reprogramming eventually overcoming their Yap addiction in late stage PDAC. In this grant we
propose a multi-faceted effort to elucidate the molecular/cellular drivers of adaptive
reprogramming in Yap-ablated, advanced PDAC tumors, and explore novel therapeutic strategies
to overcome resistance to Yap blockade. Furthermore, we will use an inducible genetic lineage-
tracing model to track how the cancer “stem/progenitor” niches contribute to PDAC invasion,
metastasis and resistance to Yap ablation. Together, these experiments will not only provide
critical insights into the mechanisms underlying PDAC plasticity, but also inform potential new
strategies to overcome therapeutic resistance in PDAC.
胰腺导管腺癌 (PDAC) 是最致命的人类癌症之一,约 95% 患有胰腺导管腺癌
由 Kras 致癌突变驱动的病例。不幸的是,试图直接抑制
致癌的 Kras 或 Ras 效应通路在治疗 PDAC 方面基本上无效,因为
抵抗力的发展。 Yap(Yes 相关蛋白),一种致癌转录
调节器,不仅是 PDAC 进展所必需的,而且还赋予对灭绝的抵抗力
晚期 PDAC 肿瘤中的致癌 Kras 信号传导和其他治疗药物。使用下一个-
一代诱导型基因工程小鼠模型,我们发现即使 PDAC
肿瘤依靠 Yap 来维持肿瘤生长和存活所需的转录输出,
具有干细胞/祖细胞样特征的肿瘤细胞亚群经历表观遗传
重新编程最终克服了 PDAC 后期的 Yap 成瘾。在这笔赠款中我们
提出多方面的努力来阐明适应性的分子/细胞驱动因素
在 Yap 消融的晚期 PDAC 肿瘤中进行重编程,并探索新的治疗策略
克服雅浦岛封锁的阻力。此外,我们将使用可诱导的遗传谱系-
追踪模型来追踪癌症“干细胞/祖细胞”生态位如何促进 PDAC 侵袭,
转移和对 Yap 消融的抵抗。总之,这些实验不仅将提供
对 PDAC 可塑性潜在机制的重要见解,同时也为潜在的新发现提供了信息
克服 PDAC 治疗耐药的策略。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Alessandro Gardini其他文献
Alessandro Gardini的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Alessandro Gardini', 18)}}的其他基金
Role of an Integrator-EGR axis in the regulation of myeloid enhancers (Admin Supp)
Integrator-EGR 轴在骨髓增强子调节中的作用(管理补充)
- 批准号:
10007301 - 财政年份:2020
- 资助金额:
$ 50.69万 - 项目类别:
Role of an Integrator-EGR axis in the regulation of myeloid enhancers
Integrator-EGR 轴在骨髓增强子调节中的作用
- 批准号:
10534872 - 财政年份:2019
- 资助金额:
$ 50.69万 - 项目类别:
Role of an Integrator-EGR axis in the regulation of myeloid enhancers
Integrator-EGR 轴在骨髓增强子调节中的作用
- 批准号:
10310455 - 财政年份:2019
- 资助金额:
$ 50.69万 - 项目类别:
Role of an Integrator-EGR axis in the regulation of myeloid enhancers
Integrator-EGR 轴在骨髓增强子调节中的作用
- 批准号:
10748543 - 财政年份:2019
- 资助金额:
$ 50.69万 - 项目类别:
Role of an Integrator-EGR axis in the regulation of myeloid enhancers
Integrator-EGR 轴在骨髓增强子调节中的作用
- 批准号:
10536618 - 财政年份:2019
- 资助金额:
$ 50.69万 - 项目类别:
Role of an Integrator-EGR axis in the regulation of myeloid enhancers
Integrator-EGR 轴在骨髓增强子调节中的作用
- 批准号:
10064637 - 财政年份:2019
- 资助金额:
$ 50.69万 - 项目类别:
相似海外基金
心房細動に対するPulsed Field Ablationの組織創傷治癒過程を明らかにする網羅的研究
阐明房颤脉冲场消融组织伤口愈合过程的综合研究
- 批准号:
24K11201 - 财政年份:2024
- 资助金额:
$ 50.69万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Targeted ablation of cerebral atherosclerosis using supramolecular self-assembly
利用超分子自组装靶向消融脑动脉粥样硬化
- 批准号:
24K21101 - 财政年份:2024
- 资助金额:
$ 50.69万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
遅延造影心臓MRIによる心房細動Ablation冷却効果の比較:28 vs. 31 mm Cryoballoon
使用延迟对比增强心脏 MRI 比较房颤消融冷却效果:28 毫米与 31 毫米 Cryoballoon
- 批准号:
24K11281 - 财政年份:2024
- 资助金额:
$ 50.69万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
InSPACE-VT_Development and Validation of Virtual Pace Mapping to Guide Catheter Ablation of Ventricular Tachycardia
InSPACE-VT_虚拟起搏测绘的开发和验证以指导室性心动过速导管消融
- 批准号:
EP/Z001145/1 - 财政年份:2024
- 资助金额:
$ 50.69万 - 项目类别:
Fellowship
CAREER: Heat Penetration Depth and Direction Control with Closed-Loop Device for Precision Ablation
职业:利用闭环装置控制热穿透深度和方向,实现精确烧蚀
- 批准号:
2338890 - 财政年份:2024
- 资助金额:
$ 50.69万 - 项目类别:
Continuing Grant
Collaborative Research: RUI: Frontal Ablation Processes on Lake-terminating Glaciers and their Role in Glacier Change
合作研究:RUI:湖终止冰川的锋面消融过程及其在冰川变化中的作用
- 批准号:
2334777 - 财政年份:2024
- 资助金额:
$ 50.69万 - 项目类别:
Continuing Grant
Collaborative Research: RUI: Frontal Ablation Processes on Lake-terminating Glaciers and their Role in Glacier Change
合作研究:RUI:湖终止冰川的锋面消融过程及其在冰川变化中的作用
- 批准号:
2334775 - 财政年份:2024
- 资助金额:
$ 50.69万 - 项目类别:
Continuing Grant
Collaborative Research: RUI: Frontal Ablation Processes on Lake-terminating Glaciers and their Role in Glacier Change
合作研究:RUI:湖终止冰川的锋面消融过程及其在冰川变化中的作用
- 批准号:
2334776 - 财政年份:2024
- 资助金额:
$ 50.69万 - 项目类别:
Continuing Grant
MRI: Acquisition of a Laser Ablation - Inductively Coupled Plasma - Triple Quadrupole - Mass Spectrometer (LA-ICP-QQQ-MS) System For Research and Education
MRI:获取用于研究和教育的激光烧蚀 - 电感耦合等离子体 - 三重四极杆 - 质谱仪 (LA-ICP-MS/MS) 系统
- 批准号:
2320040 - 财政年份:2023
- 资助金额:
$ 50.69万 - 项目类别:
Standard Grant
Collaborative Research: CDS&E: An experimentally validated, interactive, data-enabled scientific computing platform for cardiac tissue ablation characterization and monitoring
合作研究:CDS
- 批准号:
2245152 - 财政年份:2023
- 资助金额:
$ 50.69万 - 项目类别:
Standard Grant